Sarepta Therapeutics (SRPT) Non-Current Assets (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Non-Current Assets of $869.1 million for Q1 2026, down 15.86% year-over-year from $1.0 billion in Q1 2025, and up 7.06% quarter-over-quarter from $811.8 million in Q4 2025.
Sarepta Therapeutics (SRPT) Non-Current Assets (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $869.1 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 15.86% year-over-year to $869.1 million; the TTM figure through Mar 2026 stood at $3.5 billion (down 2.88% YoY), while the FY2025 annual figure was $811.8 million, down 8.76% from the prior year.
- Non-Current Assets for Q1 2026 stood at $869.1 million, up from $811.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.0 billion in Q1 2025, with the low at $525.2 million in Q1 2022.
- The 5-year median for Non-Current Assets is $740.6 million (2024), against an average of $737.3 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets jumped 38.81% in 2024, then declined 15.86% in 2026.
- Sarepta Therapeutics' Non-Current Assets stood at $570.5 million in 2022, then gained by 20.11% to $685.2 million in 2023, then increased by 29.84% to $889.7 million in 2024, then dropped by 8.76% to $811.8 million in 2025, then rose by 7.06% to $869.1 million in 2026.
- Business Quant data shows SRPT's Non-Current Assets at $869.1 million in Q1 2026, $811.8 million in Q4 2025, and $771.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 964.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 964.69 Mn |
| Mar 31, 2026 | 869.06 Mn |
| Dec 31, 2025 | 811.77 Mn |
| Sep 30, 2025 | 771.13 Mn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | 889.71 Mn |
| Sep 30, 2024 | 914.57 Mn |
| Jun 30, 2024 | 740.62 Mn |
| Mar 31, 2024 | 759.52 Mn |
| Dec 31, 2023 | 685.25 Mn |
| Sep 30, 2023 | 658.86 Mn |
| Jun 30, 2023 | 653.28 Mn |
| Mar 31, 2023 | 571.41 Mn |
| Dec 31, 2022 | 570.51 Mn |
| Sep 30, 2022 | 530.22 Mn |
| Jun 30, 2022 | 527.55 Mn |
| Mar 31, 2022 | 525.21 Mn |
| Dec 31, 2021 | 543.88 Mn |
| Sep 30, 2021 | 476.91 Mn |